

Document Type:	Clinical Study Protocol
Official Title:	A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain
NCT Number:	NCT05485805
Document Date:	13-Mar-2023

Title Page

Protocol Title: A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain

Protocol Number: 22093

Amendment Number: 3

Compound Number: BAY 2880376

Study Phase: Phase 3

Sponsor Name: Bayer HealthCare LLC, Consumer Health

Legal Registered Address: 100 Bayer Boulevard
Whippany, NJ 07981-0915, USA

Regulatory Agency Identifier Number(s): IND 140798

Approval Date: 13-Mar-2023

Confidential

The information provided in this document is strictly confidential and is intended solely for the performance of the clinical investigation. Reproduction or disclosure of this document, whether in part or in full, to parties not associated with the clinical investigation or its use for any other purpose without the prior written consent of the sponsor is not permitted.

Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the appearance of product names without these symbols does not imply that these names are not protected.

Sponsor Signatory

PPD



13-Mar-2023

PPD



Date

PPD Global Medical Affairs Pain

Bayer Consumer Health

Protocol Amendment Summary of Changes Table**Protocol Amendment 1 (Version 2.0)**

The following sections were amended from Version 1.0 to Version 2.0. Pagination was updated in this table to align with Amendment 2.

Type of Amendment: Substantial

Changes which are considered significant or substantial have been made to the following sections reflected below:

Page Number	Section Number	Paragraph or bullet point/number
28	6.1.1	Study intervention assignment At the beginning of the first treatment period, after completion of the pre-treatment baseline procedures/assessments, participants who meet the entry criteria will be sequentially assigned to a unique number in sequential order (randomization number, RNR) according to the randomization schedule 2:2:2:1:1 3:3:3:1:1 (naproxen sodium/caffeine 220/65 mg; naproxen sodium/caffeine 440/130 mg; naproxen sodium 220 mg; caffeine 100 mg; placebo) prepared prior to the study.

Protocol Amendment 2 (Version 3.0)

The following sections were amended from Version 2.0 to Version 3.0. Pagination and headers were updated in this table to align with Amendment 2.

Type of Amendment: Substantial

Page Number	Section Number	Paragraph or bullet point/number
2	Sponsor Signatory	PPD PPD PPD PPD Bayer Consumer Health

12	Objectives and Endpoints	<ul style="list-style-type: none"> Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose
15	1.3	Footnote c - Pain Intensity NRS to be completed at baseline (predose), and Pain Intensity NRS and Categorical Pain Relief will be assessed 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours (+/-5 minutes over the first 8 hours; +/-8 minutes from hours 9 through 24) post-dose. If rescue occurs, scales/questions will be completed immediately each time rescue medication is taken
19	3	<ul style="list-style-type: none"> Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose Peak PID and peak pain relief Time and cumulative proportion of achieving complete pain relief
25	5.2	17. Use of Nicotine containing products from midnight 24 hours prior to surgery until discharge from the study site or longer if so directed by the oral surgeon;
27	6	The study center will dispense a single-dose (2 tablets) of an assigned treatment within 4.5 hours post-surgery. The tablets and placebo will be administered based on a computer-generated randomization schedule (section 6.1.1) and stratified by the severity of pain experienced (moderate or severe). Moderate participants will use the lowest randomization number available and severe participants will use the highest randomization number available.

28	6.1.1	<p>At the beginning of the first treatment period, after completion of the pre-treatment baseline procedures/assessments, participants who meet the entry criteria will be randomized in the study. The randomization will be stratified by baseline pain intensity (moderate vs severe) according to the randomization schedule 3:3:3:1:1 (naproxen sodium/caffeine 220/65 mg; naproxen sodium/caffeine 440/130 mg; naproxen sodium 220 mg; caffeine 100 mg; placebo) prepared prior to the study. Participants sequentially assign will be assigned sequentially to a unique number in sequential order the lowest available number or highest available number (randomization number, RNR) for those with moderate or severe baseline pain intensity, respectively according to the randomization scheduled 3:3:3:1:1 (naproxen sodium/caffeine 220/65 mg; naproxen sodium/caffeine 440/130 mg; naproxen sodium 220 mg; caffeine 100 mg; placebo) prepared prior to the study to assure treatment balance between each stratum.</p>
29	6.1.1	<p>Participants will be numbered according to the following scheme:</p> <p style="text-align: center;">PPD</p> <p>Whereas the “Xs” will be replaced with a four five digit sequentially assigned number as each participant enters the study (e.g., first participant number will be PPD</p>
29	6.1.2	<p>Participants must be nil per os (NPO) from midnight prior to surgery until completion of surgery. If participants ingest clear liquids during this time, they may be eligible as per investigator discretion. Each participant will continue fasting, with the exception of clear liquids, until after study drug administration.</p>
30	6.1.2	<p>The Sponsor will provide sufficient quantity of the study intervention to the study site. The study center will dispense study intervention according to the randomization schedule and stratify randomization by the participant’s categorical pain intensity (moderate or severe) post-surgery.</p>

32	6.5.1	<p>Rescue medication will be dispensed in a hierarchical method starting with ibuprofen 400 mg. Should the participant not experience adequate pain relief, Hydrocodone 5 mg/Acetaminophen 325 mg tablets or other appropriate analgesics (such as an additional ibuprofen dose) may be used at the discretion of the Investigator. Rescue medication is also available on return of pain and the time of rescue medication will be recorded in the source documents. Pain assessments will be performed immediately before the first dose of rescue medication.</p>
36	8.1.6	<p>After the baseline (pre-dose) pain intensity is determined, pain intensity and pain relief will be rated by participants at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours (+/-5 minutes over the first 8 hours; +/-8 minutes from hours 9 through 24) post-dose, and immediately prior to the use of the first dose rescue medication.</p>
37	8.1.6	<p>Participants would be encouraged not to sleep before midnight and if needed, woken for assessments (up to hour 14). Participants will be allowed a 6 hour rest period and woken for the 22 hour assessment. The order of the pain assessments is Pain Intensity, then Pain Relief, then query about any AEs. At hour 24 or immediately prior to the first dose of rescue medication (if prior to hour 24), study participants will be asked to provide a Global Assessment of investigational product after completion of the other assessments. Additionally, participants will have vital signs taken after surgery, then at 1, 12 and 24 hours post-dose.</p>
43	9.3	<p>All participants in the Safety Population who provide at least one pain assessment after the first dose of the investigational product. ITT population will be used as the primary analysis for the efficacy parameters will be used as secondary to conduct the sensitivity analysis for the selected parameters.</p> <p>PP population will include all participants in ITT who do not have any major protocol violations and complete the 24 hour assessments. PP population will be used as secondary to conduct the sensitivity analysis for the selected parameters will be used as primary analysis for the efficacy parameters.</p>

44	9.4.1	A positive difference is indicative of improvement. Time-weighted Sum of Pain Intensity Differences (SPIDs) will be calculated for 2, 4, 6, 8, 12, 16, 20 and 24 hours by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake) , 22 and 24 hours, respectively.
44	9.4.1	The primary efficacy analyses population will be based on the ITT PP population.
45	9.4.1	<p>Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose. Descriptive statistics for each time point and graphical illustrations of the time effect curves will be presented.</p> <p>Time to achieve complete pain relief will be analyzed similarly as for the time to first use of rescue medication.</p> <p>Cumulative percent of participants with 'at least a 2-point PID' and cumulative percent of participants achieving complete pain relief will be plotted over time and will be analyzed using Chi-square tests.</p>

Protocol Amendment 3 (Version 4.0)

The following sections were amended from Version 3.0 to Version 4.0. Pagination was updated in this table to align with Amendment 3.

Type of Amendment: Substantial

Changes which are considered significant or substantial have been made to the following sections reflected below:

Page Number	Section Number	Paragraph or bullet point/number
16	1.3	Footnote a - Vital signs (blood pressure, pulse rate, and respiration after sitting for at least 5 minutes). On Day 1, vital signs are due pre-operatively, post-surgery, at 1 hour, 12 hours and on Day 2, 24 hours (-30 minutes pre-surgery; +30 minutes post-surgery; +/- 30 minutes from hours 1 through 24) after study medication dosing

37	8.1.2	<p>Participants will arrive at the unit at their assigned time and will have the following activities completed prior to dental surgery:</p> <ul style="list-style-type: none">• Vital signs consisting of sitting blood pressure (in triplicate with one min in between), respiratory rate and pulse after sitting for at least 5 minutes (-30 minutes);
38	8.1.6	<p>Participants who have not met the randomization criteria within 4.5 hours from last suture or 14:30 h (+/- 15 minutes) will not be randomized and may be discharged from the clinic, once deemed eligible by an Investigator.</p> <p>Additionally, participants will have vital signs taken after surgery, then at 1, 12 and 24 hours (+30 minutes post-surgery; +/-30 minutes from hours 1 through 24) post-dose.</p>
40	8.2.2	<p>Blood pressure is to be taken in triplicates, one minute apart to enhance accuracy as suggested in the FDA guidance (Assessment of Pressor Effect of Drugs, May, 2018). Pre-surgery vitals may be collected up to 30 minutes prior to time of surgery.</p>

Table of Contents

Title Page.....	1
Sponsor Signatory	2
Protocol Amendment Summary of Changes Table.....	3
Study intervention assignment	3
Table of Contents	9
Table of Tables	11
1. Protocol Summary	12
1.1 Synopsis	12
1.2 Schema.....	15
1.3 Schedule of Activities (SoA)	16
2. Introduction	17
2.1 Study Rationale.....	17
2.2 Background	17
2.3 Benefit/Risk Assessment	18
3. Objectives and Endpoints.....	20
4. Study Design	21
4.1 Overall Design	21
4.2 Scientific Rationale for Study Design	22
4.3 Justification for Dose of Active Treatment Groups.....	22
4.4 End of Study (EOS) Definition.....	24
5. Study Population	24
5.1 Inclusion Criteria	24
5.2 Exclusion Criteria	25
5.3 Lifestyle Considerations	27
5.3.1 Meals and Dietary Restrictions	27
5.3.2 Alcohol	27
5.4 Screen Failures.....	27
5.5 Run-in Failures	27
5.6 Dropouts.....	27
5.7 General Procedures	27
6. Study Intervention	28
6.1 Study Intervention(s) Administered.....	28
6.1.1 Study intervention assignment	29
6.1.2 Participant Administration.....	30
6.2 Preparation/Handling/Storage/Accountability.....	30
6.3 Measures to Minimize Bias: Randomization and Blinding	31
6.3.1 Unblinding.....	32
6.3.2 Emergency unblinding by the investigator.....	32
6.4 Study Intervention Compliance	32
6.5 Prior and Concomitant Therapy.....	32
6.5.1 Rescue Medicine.....	33
6.6 Dose Modification	33

6.7	Intervention after the End of the Study	33
7.	Discontinuation of Study Intervention and Participant	33
7.1	Discontinuation of Study Intervention	33
7.2	Participant Discontinuation/Withdrawal from the Study	34
7.3	Lost to Follow Up	34
8.	Study Assessments and Procedures	35
8.1	Efficacy Assessments	35
8.1.1	Screening Period	35
8.1.2	Pre-surgery	36
8.1.3	Impaction Score	36
8.1.4	During Surgery	37
8.1.5	Surgical Trauma Score	37
8.1.6	Postsurgery	37
8.2	Safety Assessments	39
8.2.1	Physical Examinations	39
8.2.2	Vital Signs	39
8.2.3	Clinical Safety Laboratory Assessments	40
8.2.4	Other Procedures and Variables	40
8.3	Adverse Events and Serious Adverse Events	40
8.3.1	Time Period and Frequency for Collecting AE and SAE Information	40
8.3.2	Expected Adverse Events	41
8.3.3	Method of Detecting AEs and SAEs	41
8.3.4	Follow-up of AEs and SAEs	41
8.3.5	Regulatory Reporting Requirements for SAEs	41
8.3.6	Pregnancy	42
8.4	Treatment of Overdose	42
8.5	Pharmacokinetics	42
8.6	Pharmacodynamics	42
8.7	Genetics	42
8.8	Biomarkers	42
8.9	Health Economics	43
9.	Statistical Considerations	43
9.1	Statistical Hypotheses	43
9.2	Sample Size Determination	43
9.3	Populations for Analyses	44
9.4	Statistical Analyses	44
9.4.1	Efficacy Analyses	44
9.4.2	Safety Analyses	47
9.5	Interim Analyses	47
10.	Supporting Documentation and Operational Considerations	47
10.1	Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	47
10.1.1	Regulatory and Ethical Considerations	47
10.1.2	Financial Disclosure	48
10.1.3	Funding	48
10.1.4	Informed Consent Process	48
10.1.5	Data Protection and Confidentiality	49
10.1.6	Compensation for Health Damage of Participants / Insurance	50

10.1.7	Committees Structure	50
10.1.8	Dissemination of Clinical Study Data	50
10.1.9	Data Handling and Quality Assurance	50
10.1.10	Source Documents	51
10.1.11	Missing Data	51
10.1.12	Audit and Inspection	51
10.1.13	Archiving	52
10.1.14	Study and Site Closure	52
10.1.15	Publication Policy	52
10.2	Appendix 2: Clinical Laboratory Tests	53
10.3	Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting	53
10.3.1	Definition of AE	53
10.3.2	Definition of SAE	54
10.3.3	Recording and Follow-Up of AE and/or SAE	56
10.3.4	Reporting of SAEs	59
10.4	Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information	60
10.5	Appendix 5: Participant Assessments	63
10.6	Appendix 6: Abbreviations	65
11.	References	66

Table of Tables

Table 1 – Treatments administered	28
Table 2 – Identity of study treatment	29

Table of Figures

Figure 1 – Design Overview	15
----------------------------------	----

1. Protocol Summary

1.1 Synopsis

The post-impaction dental pain model has been widely used in the evaluation of OTC and prescription analgesics for a number of reasons. Dental surgical procedures can be easily standardized, and the population of participants undergoing a given procedure is usually relatively healthy and homogeneous. In addition, there is extensive data substantiating the usefulness of the dental pain model in predicting the relative efficacy of a wide range of analgesic medications. The model has been found to be very useful for comparing several measures of analgesic efficacy, including onset, peak effect, and duration of analgesic activity (Cooper and Beaver 1976, Cooper, Desjardins et al. (2016)). This study will use the dental pain model to compare the efficacy of naproxen sodium 220mg/caffeine 65 mg with respect to its components caffeine and naproxen sodium as well as placebo.

Protocol Title: A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain

Rationale:

BHC intends to continue the development of a fixed dose combination (FDC) product of naproxen sodium and caffeine. The product is intended to temporarily relieve minor aches and pains due to minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, and toothache. The clinical development program will provide evidence in accordance to the combination drug rule set forth in 21CFR 330.10(a)(4)(iv), which includes, in part, that each active ingredient makes a contribution to the claimed effect.

Naproxen sodium was approved on March 11, 1976 as a prescription product and on January 11, 1994 as an over-the-counter medication under NDA 20-204. In the US, it is indicated as a pain reliever/fever reducer and marketed over the counter by BHC as Aleve[®] tablets, gelatin-enrobed tablets, and liquid-filled capsules (under NDA 21-920, owned by BionPharma Inc.). It is indicated for adults and children over 12 years of age, with one tablet to be taken every 8-12 hours while symptoms persist. The first dose may be taken as 2 tablets within the first hour, but should not exceed 2 tablets in any 8- to 12-hour period and no more than 3 tablets in any 24-hour period. The maximum daily limit for naproxen sodium is 660 mg for up to 10 days.

Caffeine is included in three different OTC drug monographs: internal analgesic, antipyretic, and anti-rheumatic OTC drug products (21 CFR 343); stimulant OTC drug products (21 CFR 340); and menstrual OTC drug products (21 CFR 357). The internal analgesics monograph is in the Tentative Final Monograph (TFM) state since 1998. However, subsequent FDA correspondence (1995) in response to Industry Docket Submissions permits analgesics, such as aspirin and acetaminophen, to be combined with 65 mg of caffeine, which functions as an adjuvant, potentiating the effect of the analgesic active ingredient to provide stronger relief as compared to its therapeutic dose in monotherapy. When used as an analgesic adjuvant in adults and children 12 years and older, caffeine dose can be up to 130 mg per single dose and up to 4 doses in 24 hours, which can reach 520 mg of caffeine per day. The stimulant monograph allows for products to have 100-200 mg of caffeine per dose. These products are to be taken no more than every 3-4 hours, for a total of 1600 mg of caffeine per day by adults and children 12 years and older. The menstrual drug products monograph allows for 100-200 mg of caffeine every 3 to 4 hours when used as a diuretic in adults.

This study is intended to compare the efficacy of a single tablet of naproxen sodium 220/caffeine 65 mg with respect to the single ingredients as well as placebo. This study will also examine the analgesic efficacy of two tablets of the FDC.

Objectives and Endpoints:

Objectives	Endpoints
Primary	
<ul style="list-style-type: none"> To compare a single oral dose of the FDC naproxen sodium 220mg/caffeine 65mg relative to naproxen sodium 220mg, caffeine 100 mg and placebo 	<ul style="list-style-type: none"> Sum of Pain Intensity Difference over 8 hours (SPID0-8)
Secondary	
<ul style="list-style-type: none"> To compare a single oral dose of the FDC relative to naproxen sodium 220mg, caffeine 100 mg and placebo. The assessments are made in terms of: <ul style="list-style-type: none"> Pain intensity differences Measures of pain relief Duration of analgesic efficacy Onset of pain relief as determined by the time of perceptible relief Onset of pain relief as determined by the time to meaningful relief Overall relief from pain based on measures of pain intensity and pain relief Global assessment of the investigational product To assess the safety and tolerability of the investigational product in terms of adverse events (AEs) and clinical parameters 	<ul style="list-style-type: none"> Sum of pain intensity differences from 0 to 2, 4, 6, 12 and 24 hours post-dose (SPID0-2, SPID0-4, SPID0-6, SPID6-12, SPID0-12, SPID12-16, SPID16-20, SPID12-24, SPID16-24, SPID0-24) Total pain relief from 0 to 2, 4, 6, 8, 12 and 24 hours post-dose (TOTPAR0-2, TOTPAR0-4, TOTPAR0-6, TOTPAR 6-12, TOTPAR0-8, TOTPAR0-12, TOTPAR12-16, TOTPAR16-20, TOTPAR 12-24, TOTPAR16-24 and TOTPAR0-24) Time to first use of rescue medication The cumulative proportion of participants taking rescue medication over the 24 hour period. Time to first perceptible relief measured by a stopwatch, time to meaningful relief measured by a stopwatch, and time to first perceptible relief confirmed by meaningful relief defined as the time to perceptible pain relief (the first stopwatch time) for those participants who had meaningful pain relief (the second stopwatch time) Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose Peak PID and peak pain relief Cumulative percent of participants with 'at least a 2-point PID' over time Global assessment of the investigational product Collect AE and clinical parameters

Overall Design:

This is a single center, randomized, double-blind, parallel, placebo-controlled study in participants experiencing moderate to severe postoperative dental pain. The study will consist

of a Prescreening telephone call, a Screening Visit, a one day Treatment Period and a Post-Operative phone call or visit. Eligible participants who have undergone surgical extraction of three or four third molars, two of which must be mandibular partial or full bony impacted, will be randomized into one of five treatment groups and kept in-house and evaluated for efficacy and safety at the study site through completion of all trial procedures.

Disclosure Statement: This is a parallel group treatment study with 5 arms that is participant and investigator blinded.

Intervention Model: Parallel

Primary Purpose: Treatment

Number of Arms: 5

Masking: No masking

Number of Participants:

Approximately 750 participants will be screened to achieve 540 randomly assigned to study intervention and 528 evaluable participants for an estimated total of 144 evaluable participants per active intervention group with 48 participants in the caffeine 100 mg arm and 48 participants for placebo (total of 5 groups).

Intervention Groups and Duration:

Participants will receive a single dose of study intervention of either:

- naproxen sodium/caffeine 220/65 mg
- naproxen sodium/caffeine 2 x 220/65 mg
- naproxen sodium 220 mg
- caffeine 100 mg
- or placebo

with pain intensity, pain relief and onset of pain relief assessments performed over the next 24 hours.

Data Monitoring Committee: No

1.2 Schema**Figure 1 – Design Overview**

	Screening Phase	Treatment Phase					Follow up Phase
Trial Days	Day -28 to -1	Day 1 Pre-surgery	Day 1 Surgery	Day 1 Post-surgery	Day 1	Day 2	2-5 days after discharge
		Check-in to study site	Surgical teeth extraction	Categorical pain NRS pain	★ Stopwatch method NRS pain, Pain relief	Stopwatch method NRS pain Pain relief Global assessment	Phone call or visit

★ = randomized study intervention of:

naproxen sodium/caffeine 220/65 mg;
 naproxen sodium/caffeine 2 x 220/65 mg;
 naproxen sodium 220 mg;
 caffeine 100 mg;
 or placebo.

1.3 Schedule of Activities (SoA)

Protocol Activities	Screening Visit (within 28 days prior to oral surgery)	Dosing Period <i>Inpatient</i>		End of Trial Call or Visit (2-5 days after discharge)
		Day 1	Day 2	
Written Informed Consent	X			
Inclusion/Exclusion Reviewed	X	X		
Medical/Medication History (incl. caffeine consumption)	X	X		
Physical and Oral Examination	X			
Vital Signs ^a	X	X	X	
Urine for Drug Screen	X	X		
Breath or saliva alcohol test	X	X		
Dental x-ray examination	X			
Urine Pregnancy Test (if applicable)	X	X		
Admission to Unit		X		
Oral surgery (between 0530 h and 1030 h)		X		
Randomization Number Assigned		X		
Investigational Product Administration		X		
Surgical Trauma Rating		X		
Stop watch method (perceptible and meaningful relief)		X	X	
Categorical Pain Rating Scale ^b		X	X	
Pain Intensity Numerical Rating Scale (NRS) ^c		X	X	
Categorical Pain Relief Rating Scale ^c		X	X	
Global Assessment of Pain Relief ^d			X	
Concomitant Medications		X	X	X
Adverse Events Assessed	X	X	X	X
Discharge from Unit the afternoon/evening of Day 2			X	

^a vital signs (blood pressure, pulse rate, and respiration after sitting for at least 5 minutes). On Day 1, vital signs are due pre-operatively, post-surgery, at 1 hour, 12 hours and on Day 2, 24 hours (-30 minutes pre-surgery; +30 minutes post-surgery; +/- 30 minutes from hours 1 through 24) after study medication dosing

^b to be completed prior to dosing

^c Pain Intensity NRS to be completed at baseline (predose), and Pain Intensity NRS and Categorical Pain Relief will be assessed 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours (+/-5 minutes over the first 8 hours; +/-8 minutes from hours 9 through 24) post-dose. If rescue occurs, scales/questions will be completed immediately each time rescue medication is taken

^d assessment will be completed immediately before first rescue medication is taken or at 24 hours post-dose

2. Introduction

In addition to the information provided below, please also refer to the Aleve Drug Facts Label (DFL) and the DFL of caffeine for any additional data on these products.

2.1 Study Rationale

BHC intends to continue the development of a fixed dose combination (FDC) product of naproxen sodium and caffeine. The product is to be used for the temporary relief of minor aches and pains due to minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, and toothache.

Naproxen sodium was approved on March 11, 1976 as a prescription product and on January 11, 1994 as an over-the-counter medication under NDA 20-204. In the US, it is indicated as a pain reliever/fever reducer and marketed over the counter by BHC as Aleve tablets, gelatin-enrobed tablets, and liquid-filled capsules (under NDA 21-920, owned by BionPharma Inc.). It is indicated for adults and children over 12 years of age, with one tablet to be taken every 8-12 hours while symptoms persist. The first dose may be taken as 2 tablets within the first hour, but should not exceed 2 tablets in any 8- to 12-hour period and no more than 3 tablets in any 24-hour period. The maximum daily limit for naproxen sodium is 660 mg for up to 10 days.

Caffeine is included in three different OTC drug monographs: internal analgesic, antipyretic, and anti-rheumatic OTC drug products (21 CFR 343); stimulant OTC drug products (21 CFR 340); and menstrual OTC drug products (21 CFR 357). The internal analgesics monograph is in the Tentative Final Monograph (TFM) stage since 1998. However, subsequent FDA correspondence (1995) in response to Industry Docket Submissions now permits analgesics, such as aspirin and acetaminophen, to be combined with 65 mg of caffeine, which functions as an adjuvant, potentiating the effect of the analgesic active ingredient to provide stronger relief as compared to its therapeutic dose in monotherapy. When used as an analgesic adjuvant, in adults and children 12 years and older, caffeine dosing can be up to 130 mg per single dose and up to 4 doses in 24 hours, which can reach 520 mg of caffeine per day. The stimulant monograph allows for products to have 100-200 mg of caffeine per dose. These products are to be taken no more than every 3-4 hours, for a total of 1600 mg of caffeine per day by adults and children 12 years and older. The menstrual drug products monograph allows for 100-200 mg of caffeine every 3 to 4 hours when used as a diuretic in adults.

The clinical development program will provide evidence in accordance to the combination drug rule set forth in 21CFR 330.10(a)(4)(iv), which includes, in part, that each active ingredient makes a contribution to the claimed effect.

This study will also examine the analgesic efficacy of two tablets of the FDC vs. one tablet.

2.2 Background

Naproxen sodium is the sodium salt of naproxen, an aryl propionic acid derivative in the nonsteroidal anti-inflammatory drugs (NSAID) class. Naproxen exerts its analgesic, antipyretic and anti-inflammatory effects by inhibition of prostaglandin synthesis through its non-selective, reversible inhibition of the cyclo-oxygenase (COX) enzymes. Naproxen inhibits the formation of COX-1 dependent thromboxane synthase, A2 (TXA2), which reduces platelet aggregation, and the COX-2 dependent prostacyclin (PGI2) which play a role

in vasodilation associated with inflammation and prostaglandins (i.e. PGE₂) which contribute to sensation of pain (Capone, Tacconelli et al. 2004, Grosser, Theken et al. 2017).

In the United States, naproxen has been marketed as a prescription medication since 1976 under the brand name Naprosyn[®]. Its sodium salt, naproxen sodium, was first sold under the trade name Anaprox[®] in 1980. In 1994, the US FDA approved naproxen sodium tablets (using the brand name Aleve[®]), 220 mg for over-the-counter (OTC) use. Aleve[®] is indicated for the temporary relief of minor aches and pains due to minor pain of arthritis, muscular aches, backaches, menstrual cramps, headaches, toothaches, and the common cold. It also temporarily reduces fever. As an OTC medication, Aleve[®] should not be taken for longer than 10 days for pain or 3 days for fever unless otherwise directed by a physician.

Caffeine is a methyl xanthine, found in plants and is generally consumed as coffee, tea, or cocoa. It is a central nervous system and metabolic stimulant, used to reduce fatigue and enhance mental alertness. It can also stimulate the respiratory center, thereby increasing the rate and depth of respiration. It can also facilitate the performance of muscles. Caffeine has been shown to enhance the effectiveness of various pain relievers, so it is accepted as an adjuvant to analgesics such as acetaminophen, ibuprofen and aspirin (Laska, Sunshine et al. 1984, Sawynok and Yaksh 1993, Diener, Pfaffenrath et al. 2005, Derry, Derry et al. 2014, Derry, Wiffen et al. 2015, Lipton, Diener et al. 2017).

While caffeine may affect various physiological processes, its main mode of action as an analgesic adjuvant is through antagonism of adenosine receptors in the brain. The reduction in adenosine activity results in reduced perception of pain. Caffeine can also exhibit mood enhancing and stimulatory properties (Sawynok and Yaksh 1993).

This proposed product is intended to be a tablet with a fixed dose combination of 220 mg naproxen sodium and 65 mg caffeine based on the recently completed dose ranging study. The purpose of this product is to provide temporary relief of minor aches and pains due to minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, and toothache for adults and children over 12 years of age. Its posology will be similar to Aleve[®], with one tablet to be taken every 8-12 hours while symptoms persist. The first dose may be taken as 2 tablets within the first hour, but should not exceed 2 in any 8 to 12 hours period and no more than 3 in any 24 hour period. Thus, the maximum daily limit will be 660 mg naproxen sodium and 195 mg caffeine.

This pivotal efficacy study is intended to examine the analgesic effect of this FDC compared to its components, naproxen sodium and caffeine to satisfy the combination rule set forth in 21CFR 330.10(a)(4)(iv).

2.3 Benefit/Risk Assessment

Participants who need to have third molar extraction will be solicited to participate in this study. Participants who consent to participate may benefit by receiving a medical exam, dental radiographs and no-cost surgical procedures for teeth extraction. Furthermore, post-surgical participants will be provided continuous nursing care for approximately 24 hours after surgery. Potential risks of the surgical procedure include pain, dry socket, infection, swelling, bleeding, trismus, and lip or tongue numbness. Potential risks related to local anesthesia and mild sedation include paresthesia and drowsiness. Participants who experience a treatment failure can have the option of taking a standard rescue medication commonly used for post-operative pain relief. Potential study medication benefit will be relief of postsurgical pain, which is highly

prevalent following extraction of wisdom teeth. Potential risks of a single dose of OTC study medication are low and described in the Drug Facts Label.

During the study, participants will be closely monitored for evidence of adverse events. Weighing between the potential risks associated with the study, and given the ability to mitigate risks through close monitoring and routine peri-operative care, this study is considered clinically and ethically acceptable.

More detailed information about the known and expected benefits and risks and reasonably expected adverse events may be found in the naproxen sodium Investigator's Brochure and Aleve® Drug Facts Label.

Caffeine has been proven to act as an analgesic adjuvant, providing up to 40% more relief than analgesics alone (Laska, Sunshine et al. 1984). While the analgesia-enhancing effect of caffeine has not been extensively studied with naproxen sodium, a preliminary study (Fricke 1994) showed a positive effect analogous to the results of studies with ibuprofen, another member of the aryl propionic acetic acid family of NSAIDs (Derry, Wiffen et al. 2015). The results of a recently completed dose ranging study with the proposed FDC also showed the beneficial effect of caffeine in enhancing the analgesic effect of naproxen sodium.

In regards to safety, caffeine is included in the monographs for stimulant OTC drug products (21 CFR 340) and for internal analgesic, antipyretic, and anti-rheumatic OTC drug products (21 CFR part 343) as analgesic adjuvant. Although it is generally accepted that 300 mg to 400 mg of caffeine daily may be safely taken by the general population (McGuire 2014), several potentially vulnerable populations have been identified. After a review of available data, Health Canada recommended that women of reproductive age restrict caffeine intake to no more than 300 mg daily, and that children up to 12 years restrict intake to no more than 2.5 mg per kilogram of bodyweight. During pregnancy, the American College of Obstetrics and Gynecology has recommended no more than 200 mg caffeine intake daily (ACOG 2010). Finally, consumers (particularly children) on anticonvulsants or sympathomimetics, as well as consumers with known cardiovascular disease should probably limit caffeine intake.

Risks to vulnerable populations identified above will be addressed through labeling. For example, the proposed label will restrict the product to the same population as the current Aleve® product, which is not indicated for children younger than 12 years old and instructs women to avoid taking NSAIDs around 20 weeks or later in pregnancy. Similarly, the proposed label instructs consumers on any prescription drugs or with any concurrent disease (which includes cardiovascular conditions and seizure disorders) also to consult a physician before use. Finally, the proposed label will include all the necessary instructions for safe and effective use including contraindications, applicable warnings and precautions, and undesirable effects. No further risk-minimization measures are considered necessary for this new product, and its benefit-risk balance is expected to be positive.

3. Objectives and Endpoints

Objectives	Endpoints
Primary	
<ul style="list-style-type: none"> To compare a single oral dose of the FDC relative to naproxen sodium 220mg, Caffeine 100 mg and placebo 	<ul style="list-style-type: none"> Sum of Pain Intensity Difference over 8 hours (SPID 0-8)

Objectives	Endpoints
Secondary	
<ul style="list-style-type: none"> To compare a single oral dose of the FDC relative to naproxen sodium 220mg, caffeine 100 mg and placebo. The assessments are made in terms of: <ul style="list-style-type: none"> Pain intensity differences Measures of pain relief Duration of analgesic efficacy Onset of pain relief as determined by the time of perceptible relief Onset of pain relief as determined by the time to meaningful relief Overall relief from pain based on measures of pain intensity and pain relief Global assessment of the investigational product To assess the safety and tolerability of the investigational product in terms of adverse events (AEs) and clinical parameters 	<ul style="list-style-type: none"> Sum of pain intensity differences from 0 to 2, 4, 6, 12 and 24 hours post-dose (SPID0-2, SPID0-4, SPID0-6, SPID6-12, SPID0-12, SPID12-16, SPID16-20, SPID12-24, SPID16-24, SPID0-24) Total pain relief from 0 to 2, 4, 6, 8, 12 and 24 hours post-dose (TOTPAR0-2, TOTPAR0-4, TOTPAR0-6, TOTPAR6-12, TOTPAR0-8, TOTPAR0-12, TOTPAR12-16, TOTPAR16-20, TOTPAR12-24, TOTPAR16-24, and TOTPAR0-24) Time to first use of rescue medication The cumulative proportion of participants taking rescue medication over the 24 hour period. Time to first perceptible relief measured by a stopwatch, time to meaningful relief measured by a stopwatch, and time to first perceptible relief confirmed by meaningful relief defined as the time to perceptible pain relief (the first stopwatch time) for those participants who had meaningful pain relief (the second stopwatch time) Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose Peak PID and peak pain relief Time and cumulative proportion of achieving complete pain relief Cumulative percent of participants with 'at least a 2-point PID' over time Global Assessment of the investigational product Collect AE and clinical parameters

4. Study Design

4.1 Overall Design

Design Overview

This is a single center, randomized, double-blind, parallel, placebo-controlled study in participants experiencing moderate to severe postoperative dental pain. The study will consist of a Prescreening telephone call, a Screening Visit, a one day Treatment Period and a Post-Operative phone call or visit. Eligible participants who have undergone surgical extraction of three or four third molars, 2 of which were mandibular partial or full bony impacted third molars will be kept in-house and evaluated for efficacy and safety at the study site through completion of all trial procedures.

Qualified participants will then be randomized into one of five treatments. Approximately 750 participants will be screened prior to surgery. Approximately 540 will have surgery and approximately 528 will be randomized to a specific treatment.

Screening Phase

Eligible participants will be screened and selected up to 28 days prior to oral surgery and dosing with investigational product (study intervention).

Treatment Phase

Following selection, qualified participants will enter the Treatment Phase and be scheduled for their surgical teeth extractions. After completion of the surgical teeth extractions, participants will remain at the study site for observation. Participants with appropriate pain requirement will be randomized into one of five (5) treatment groups receiving study intervention. Participants will rate their pain severity and pain relief over the next 24 hours. Onset of analgesia will be measured using a two stopwatch approach. The first stopwatch will be used to capture the time when any pain relief is first perceived. The second stopwatch will be used to capture the time when pain relief becomes meaningful to the participant. After completion of all trial procedures, participants will be discharged from the study site.

All participants are required to remain at the study center and complete all relevant assessments regardless of rescue.

Follow-Up Phase

Participants will be evaluated at a post-operative visit/call approximately 2-5 days after discharge for follow up for any adverse events or medications not known at the time of treatment.

The duration of each participant's participation will be approximately 37 days. For an overview on the study design and study procedures (see [Figure 1](#)).

4.2 Scientific Rationale for Study Design

The study is designed specifically to measure the analgesic effectiveness and capture side effect profiles of naproxen sodium and caffeine FDC compared to the individual active ingredients on acute post-surgical dental pain in healthy participants who could benefit from the administration of an analgesic medication. The molar impaction dental pain model has been widely employed with OTC and prescription pain medications, since it is easily standardized, and the participants are relatively healthy and homogeneous. In addition, there are extensive data substantiating the usefulness of the dental pain model in predicting the relative efficacy of a wide range of analgesic medications by comparing several measures of analgesic efficacy, including onset, peak effect, and duration of analgesic activity (Cooper, 2010, Cooper 1976, Kleinert, 2008).

Time to onset will be measured using a double stopwatch method. The double-stopwatch method for measuring first perceptible relief and meaningful relief was developed using the dental pain model (Desjardins 2002). After ingesting the study medication, the participant is asked to depress a stopwatch button when first perceiving any relief (First Perceptible Relief). If and when this stopwatch is depressed, the participant is then given a second stopwatch and asked to depress the button when the relief is perceived as meaningful (Meaningful Relief). Using this method, onset to First Perceptible and Meaningful Relief can be quantified to the nearest minute. This method has been proven to be sensitive and reliable for measuring analgesic onset (Cooper 2010).

The endpoints and study design are consistent with most recent Guidance by FDA and methods advocated by experts (Cooper 2016 and Singla 2014). Additionally, if a participant does not get sufficient pain relief, then rescue medication approved for treating acute pain (e.g., hydrocodone/acetaminophen) may be requested and will be provided under the supervision of the study site staff.

4.3 Justification for Dose of Active Treatment Groups

Participants will receive a single dose of study intervention, in order to provide an analgesic effect in participants who experience post-surgical dental pain.

The recommended amount of naproxen sodium in the new fixed dose combination product is based on currently marketed Aleve®. Its safety and efficacy is well characterized throughout more than 20 years of use in the over-the-counter setting.


The amount of caffeine to be tested in this pivotal efficacy study is 65 mg per unit dose based on the results of our dose ranging study which matches the dose permitted in the OTC monograph for adjuvant products. Moreover, in the written response at the End of Phase 2 the FDA was in agreement with BCH to investigate the use of 65 mg of caffeine in the proposed FDC.

The dose ranging study was submitted to the IND on September 15, 2020 (seq. 0013). This single center, single dose, randomized, double blind, parallel study in post-surgical dental pain compared one and two tablet doses of the FDC with naproxen sodium 220 mg and 65 or 100 mg caffeine against 220 mg naproxen sodium, 100 mg caffeine and placebo. The participants were healthy male and females subjects 16 years of age and older who were scheduled to have 3 or 4 third molars extracted. A total of 193 participants were randomized (n=32 in each naproxen sodium containing treatment arms, 16 in caffeine-only arm and 17 in placebo group) and 191 participants completed the study per protocol.

The primary endpoint was the sum of pain intensity differences over 8 hours (SPID0-8). Secondary endpoints included other SPID values as well as total pain relief values including TOTPAR 0-8, TOTPAR 0-12. Other efficacy measures were pain intensity differences (PID) and pain relief scores at every timepoint and at peak. Duration of analgesic effect, onset of action (using a double watch method) and Global assessment and safety variables as adverse events were also collected in the study.

All FDC treatment groups had higher SIPD0-8 than the single ingredient arms, and placebo. The differences in SPID0-8 between the FDCs and naproxen sodium was higher for the FDC containing 65 mg caffeine than the FDC with 100 mg caffeine (6.44 and 0.84, respectively). For both caffeine doses (65 and 100 mg/tablet), the 2-tablet dose provided greater efficacy than the corresponding 1 tablet dose. Secondary efficacy endpoints showed a similar trend for a greater enhancement of efficacy for both 1 tablet and 2 tablet doses of the NapS/Caff FDC with 65 mg caffeine.

Figure 2. Summed Pain Intensity Difference from 0-8 hours



Current marketed analgesic combination products of caffeine with acetaminophen or aspirin (e.g. Excedrin), recommend a dose of 2 tablets up to three to four times daily, i.e. the dose of caffeine is up to 130 mg per single dose (2 tablets) and can reach 520 mg daily (up to 8 tablets per day). Newly marketed fixed dose combination ibuprofen plus caffeine products in Europe (Thomopyrin Tension Duo and Iprafeine: ibuprofen 400mg and caffeine 100 mg) allow for daily dosage of up to three tablets totaling 1200 mg Ibuprofen and 300 mg Caffeine.

Taking 1-2 tablet of the proposed product with 65 mg of caffeine per tablet will add up to only 130 mg caffeine if the consumer takes two tablets as the initial dose. A limit of 3 tablets per 24 hours will equal 195 mg of caffeine per day. Therefore, the total daily intake of

caffeine as proposed in this fixed dose combination product is well below the currently permitted limits in the relevant OTC drug monographs and should not pose any safety concerns. Moreover, the efficacy and safety of this FDC product will be evaluated through the proposed studies in addition to those completed.

4.4 End of Study (EOS) Definition

A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities. Trial site will have the option of either contacting participants within 2 to 5 days after surgery (by phone) or scheduling participants for an office appointment, depending on their standard of care policies, to assess the occurrence or persistence of AEs, any medications taken, and for adequate treatment and follow up.

Primary completion

The primary completion is defined as the date of the last visit of the last participant for the primary outcome.

5. Study Population

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

The participant population will consist of healthy individuals who are status post extraction of three or four third molars, two of which were mandibular partial or full bony impactions.

5.1 Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

1. Healthy, ambulatory, male or female volunteers 16 years of age or older;
2. Body mass index 18.5 to 35.0 kg/m² inclusive as measured by the NIH BMI Calculator;
3. Participants will undergo surgical extraction of three or four third molars, two of which must be mandibular molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must have a trauma rating of mild or moderate and meet one of the following scenarios:
 - two full bony impactions
 - two partial bony impactions
 - one full bony impaction in combination with one partial bony impaction

Supernumerary teeth present may also be removed at the discretion of the oral surgeon;

4. Have not taken any form of medication, nutritional supplements with analgesic properties (e.g. GABA, turmeric) or herbal supplements (i.e., St. John's Wort) within 5 days of admission (except for oral contraceptives, prophylactic antibiotics, multivitamin supplements, or other routine medications to treat benign conditions (such as antibiotics to treat acne), and agree not to take any medication (other than that provided to them) throughout the study;
5. Female participants of childbearing potential must: a) be using a medically acceptable form of birth control [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier] for at least 1 month prior to screening (3 months on oral contraceptives); b) abstain from sexual intercourse for at least 1 month prior to screening; or c) participate exclusively in a same sex relationship for at least 1 month prior to screening. In addition, female participants of childbearing potential must have a negative pregnancy test at Screening and prior to study drug administration. Female participants of non-childbearing potential must be amenorrheic for at least two years or have undergone surgical sterilization (i.e. tubal ligation/occlusion, hysterectomy and/or bilateral oophorectomy);
6. Have not consumed alcoholic beverages, or foods and beverages containing caffeine (examples; coffee, tea, chocolate, and colas) for 24 hours and for 2 days prior to surgery, respectively and agree not to consume any of these foods or beverages throughout their stay at the study site;
7. Use of only short-acting local anesthetic (e.g., mepivacaine or lidocaine) preoperatively, with or without a vasoconstrictor and nitrous oxide at the discretion of the Investigator;
8. Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0-10 pain intensity NRS within 4.5 hours post-surgery;
9. Ability to understand and follow study-related instructions;
10. Be willing and able to participate in all scheduled visits, treatment plan, and trial procedures according to the clinical protocol;
11. Capable of giving signed informed consent as described in Section 10.1.4 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

5.2 Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

1. History of hypersensitivity to naproxen sodium, caffeine, ibuprofen, NSAIDS, aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the investigational products;
2. Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension and cardiac arrhythmia), hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;

3. Participants with the following medical conditions may be eligible at the discretion of the investigator: ADHD on a stable dose regimen of methylphenidate/(dextro) amphetamine for at least 6 months; participants with hypothyroidism on a stable dose of synthetic thyroid hormone for at least 6 months;
4. Have received any form of treatment in the form of medication for depression in the past 6 months or any form of psychotropic agent (including selective serotonin uptake inhibitors [SSRI] but excluding ADHD medications described above) within the last 6 months;
5. Relevant concomitant disease such as asthma (exercise induced asthma is permitted);
6. Current or past history of gastrointestinal ulceration, gastrointestinal bleeding or other bleeding disorder(s);
7. Acute illness or active local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator;
8. Use of any OTC or prescription medications with which the administration of naproxen, acetaminophen, ibuprofen, any other NSAID, (e.g., tramadol) or if a medication is contraindicated;
9. Use of any medications within 5 days of surgery until discharge from the study site (except oral contraceptives, prophylactic antibiotics, synthetic thyroid hormones, methylphenidate or medications to treat benign conditions such as antibiotics to treat acne);
10. Use of caffeine within 2 days prior to the study
11. Habits of high consumption of caffeine (>400 mg/day equivalent to about 3-4 cups of coffee per day)
12. Females who are planning to become pregnant, are pregnant or lactating;
13. Habituation to analgesic drugs including opioids (i.e., routine use of oral analgesics 5 or more times per week for greater than 3 weeks within the past 2 years);
14. Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine consumption of 3 or more alcohol containing beverages per day; Alcohol containing beverages are defined as one beer (5%), one glass of wine (11%) and one shot (40%) hard liquor;
15. Positive urine drug screen or alcohol test on day of surgery;
16. Surgeon's trauma rating of severe following surgery;
17. Use of Nicotine containing products from 24 hours prior to surgery until discharge from the study site or longer if so directed by the oral surgeon;
18. Member or first-degree relative of study staff or the Sponsor directly involved in the study;
19. Unwilling or unable to comply with all requirements outlined in the protocol;
20. Participants with a medical disorder, condition, or history of such that could impair the participant's ability to participate or complete this trial in the opinion of the investigator;
21. Previous enrollment in this study.

5.3 Lifestyle Considerations

No lifestyle restrictions are required.

5.3.1 Meals and Dietary Restrictions

Participants will be instructed not to consume food that contains caffeine (e.g., chocolate, ice cream) two days prior to surgery.

5.3.2 Alcohol

Participants will be instructed not to consume alcohol beverages 24 hours prior to surgery.

5.4 Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to study intervention. A minimal set of screen failure information is required to ensure transparent reporting of screen failure to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).

Individuals who do not meet the criteria for participation in this study (screen failure) due to scheduling surgery may be rescreened. A previous dental x-ray if taken during the original screening visit can be used when rescreened. Rescreened participants should be assigned a new participant number.

5.5 Run-in Failures

A participant who, for any reason terminates the study after surgery and prior to the start of study drug administration (e.g., not meeting pain threshold) is regarded as a “Run-in failure”.

5.6 Dropouts

A participant who discontinues study participation prematurely for any reason is defined as a “dropout” if the participant has been randomized and administered at least one dose of study drug.

5.7 General Procedures

In all cases, the reason for withdrawal must be recorded on the screening log and in the participant's medical records.

The participant may object to the generation and processing of post-withdrawal data as specified in Section [10.1.8](#).

Details for the premature termination of the study as a whole (or components thereof) are provided in Section [10.1.14](#) (Premature termination of the Study).

6. Study Intervention

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

The study center will dispense a single-dose (2 tablets) of an assigned treatment within 4.5 hours post-surgery. The tablets and placebo will be administered based on a computer-generated randomization schedule (section 6.1.1) and stratified by the severity of pain experienced (moderate or severe). Moderate participants will use the lowest randomization number available and severe participants will use the highest randomization number available. Participants who characterize their pain severity as mild and have a NRS <5 will not receive treatment and will be discharged from the study site with a prescription for pain medication, if deemed safe, by the Investigator.

6.1 Study Intervention(s) Administered

Table 1 – Treatments administered

Treatment (condition)	Dose / route	Amount / form	Frequency of administration
Naproxen sodium and caffeine 220/65 mg (postsurgery)	220/65 mg / orally	1 / tablet*	single dose
Naproxen sodium and caffeine 440/130 mg (postsurgery)	440/130 mg / orally	2 / tablets	single dose
Naproxen sodium 220 mg (postsurgery)	220 mg / orally	1 / tablet*	single dose
Caffeine 100 mg (postsurgery)	100 mg / orally	1 / tablet*	single dose
Placebo (postsurgery)	NA / orally	2 / tablets	single dose

*participants assigned to these study interventions will also receive a second tablet of placebo so that blinding is maintained.

Table 2 – Identity of study treatment

Treatment (UI)	Naproxen / Caffeine (1614204-029)	Naproxen (1600169)	Caffeine (not applicable)	Placebo (1614204-027)
Dose	one or two tablets	one tablet	one tablet	two tablets
Pharmaceutical Form	tablet	tablet	tablet	tablet
Strength	220/65 mg	220 mg	100 mg	not applicable
Formulation	naproxen sodium caffeine microcrystalline cellulose copovidone talc magnesium stearate blue film coating	naproxen sodium FD&C blue #2 lake hypromellose magnesium stearate microcrystalline cellulose polyethylene glycol povidone talc titanium dioxide	caffeine calcium stearate lactose microcrystalline cellulose silicon dioxide	dibasic calcium phosphate dihydrate magnesium stearate microcrystalline cellulose blue film coating
Route of administration	orally with a full glass of water (i.e. about 8 ounces or 240 mL)	orally with a full glass of water (i.e. about 8 ounces or 240 mL)	orally with a full glass of water (i.e. about 8 ounces or 240 mL)	orally with a full glass of water (i.e. about 8 ounces or 240 mL)
Batch Number	see study file	see study file	see study file	see study file
Trade Name and Manufacturer	Bayer Morristown, NJ USA	Aleve® Bayer Bitterfeld, Germany	Bell Pharmaceuticals Belle Plaine, MN USA	Bayer Morristown, NJ USA

6.1.1 Study intervention assignment

At the beginning of the first treatment period, after completion of the pre-treatment baseline procedures/assessments, participants who meet the entry criteria will be randomized in the study. The randomization will be stratified by baseline pain intensity (moderate vs severe) according to the randomization schedule 3:3:3:1:1 (naproxen sodium/caffeine 220/65 mg; naproxen sodium/caffeine 440/130 mg; naproxen sodium 220 mg; caffeine 100 mg; placebo) prepared prior to the study. Participants will be assigned sequentially to the lowest available number or highest available number (randomization number, RNR) for those with moderate or severe baseline pain intensity, respectively to assure treatment balance between each stratum.

Participants will be numbered according to the following scheme:

PPD

Whereas the “Xs” will be replaced with a five digit sequentially assigned number as each participant enters the study (e.g., first participant number will be PPD

The unique participant identifier number will be assigned in numerical order prior to dosing. Participants who characterize their pain severity as *mild* and <5 on the NRS will not receive treatment and be withdrawn from the study.

Once a number has been assigned to a participant, it cannot be reassigned to another participant.

Participants completing the Screening Visit, if not scheduled for surgery the same day, will return to the trial site within 28 days, and if they continue to meet inclusion/exclusion criteria post-surgery will be randomized to one of five treatment groups:

- naproxen sodium/caffeine 220/65 mg (1 tablet plus 1 tablet of placebo)
- naproxen sodium/caffeine 220/65 mg (2 tablets)
- naproxen sodium 220 mg (1 tablet plus 1 tablet of placebo)
- caffeine 100 mg (1 tablet plus 1 tablet of placebo)
- placebo (2 tablets)

Participants will be assigned to treatment groups in accordance with the randomization schedule. The Sponsor will provide a randomization schedule to the study site.

6.1.2 Participant Administration

Each participant will receive a single dose of the study intervention. Participants receive the study intervention with a full glass of non-refrigerated, non-carbonated water (about 8 ounces or 240 mL). Study intervention will be administered using dosing cups. Selection and preparation of the proper dose will be performed by an unblinded study team member using the provided randomization schedule (see Section 6.3). The Investigator or a designee will supervise the study intervention administration in a manner, which maintains the masking conditions (blinding of the participant).

Participants must be nil per os (NPO) from midnight prior to surgery until completion of surgery. If participants ingest clear liquids during this time, they may be eligible as per investigator discretion. Each participant will continue fasting, with the exception of clear liquids, until after study drug administration.

6.2 Preparation/Handling/Storage/Accountability

All study drugs will be labeled according to the requirements of local law and legislation. Label text will be approved according to the sponsor’s agreed procedures, and a copy of the labels will be made available to the study site upon request.

For all study drugs, a system of numbering in accordance with all requirements of Good Manufacturing Practice (GMP) will be used, ensuring that each dose of study drug can be traced back to the respective bulk batch of the ingredients. Lists linking all numbering levels will be maintained by the sponsor’s clinical supplies Quality Assurance (QA) group.

A complete record of batch numbers and expiry dates of all investigational products as well as the labels will be maintained in the clinical supply file.

The source of test and reference products will be documented in the clinical supply file.

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention. Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).

The Sponsor will provide sufficient quantity of the study intervention to the study site. The study center will dispense study intervention according to the randomization schedule and stratify randomization by the participant's categorical pain intensity (moderate or severe) post-surgery. Study intervention will be supplied to the study center in multi-dose bottles and dispensed by an unblinded member of the study team.

All study drugs will be stored at the investigational site in accordance with GCP requirements and the instructions given by the clinical supplies department of the sponsor (or its affiliate/CRO), and will be inaccessible to unauthorized personnel. Special storage conditions and a complete record of batch numbers and expiry dates can be found in the Sponsor's study file; the site-relevant elements of this information will be available in the investigator site file. On the day of receipt, the responsible site personnel will confirm receipt of study investigational products in writing. The personnel will use the study investigational products only within the framework of this clinical study and in accordance with this protocol. Receipt, distribution, return and destruction (if any) of the study drug must be properly documented according to the sponsor's agreed and specified procedures.

6.3 Measures to Minimize Bias: Randomization and Blinding

On Day 1, participants will be assigned a unique number (randomization number) in ascending numerical order at the study site. The randomization number encodes the participant's assignment to one of the five (5) arms of the study, according to the randomization schedule generated prior to the study by the Sponsor. Each participant will be dispensed blinded study intervention, labeled with his/her unique randomization number, throughout the study.

Participants enrolled in the trial, investigators and their staff involved in protocol procedures or who are involved in data collection, data entry and data analysis will be blinded to the identity of the treatments until the database is locked. The study monitor will conduct product accountability after database lock. To preserve blinding, participants will be blindfolded during administration of study medication. Study drug will be dispensed by an unblinded study team member based on the randomization schedule. That team member may have no other role in the study conduct and may not reveal the study drug's identity to any members of the blinded study team.

Sponsor will supply study medication in bulk containers. Selection of the proper dose for an individual participant will be performed by an unblinded study team member using the provided randomization schedule. The unblinded study team member will withdraw the appropriate study medication from the bulk container and transfer it to a dispensing cup. All

study interventions must be administered as 2 tablets per participant. Some study interventions require the addition of a placebo tablet. The unblinded study team member will then bring the study medication to the treatment room where it will be dispensed to the participant by the study team member. The unblinded study team member should have no other responsibilities in the study.

6.3.1 Unblinding

In the case of a medical emergency, such as serious adverse events (SAE), breaking the blind may become necessary during the trial

In compliance with applicable regulations, in the event of a serious unexpected adverse event (SUSAR) related to the blinded treatment, the participant's treatment code will usually be unblinded before reporting to the health authorities, ethic committees and investigators (see Section 8.3.5).

6.3.2 Emergency unblinding by the investigator

The investigator must report the blind break in conjunction with a SAE within 24 hours of becoming aware of the effect as defined in Section 10.3.1. Participants who have been unblinded will not be included in the ITT or PP efficacy analysis.

6.4 Study Intervention Compliance

The administration of the study medication will be supervised by an unblinded member of the Investigator's team. This person will perform the oral cavity inspection after study drug administration and document that the participant receives the treatment as planned.

6.5 Prior and Concomitant Therapy

The following treatments are prohibited from screening and during the study:

- Use of any form of medication or herbal supplements, including GABA and turmeric, or curcumin, within 5 days of surgery that would confound the evaluation of the study product, until discharge from the study site;
- Use of acetaminophen, naproxen, hydrocodone/acetaminophen, ibuprofen, aspirin, or other NSAIDs or any other pain reliever (OTC or prescription) within 5 days before surgery;
- Use of alcoholic beverages after midnight prior to surgery and throughout the evaluation period;

All medications (prescription and nonprescription products, vitamin and herbal products) taken by the participant from 30 days prior to Screening to End of Trial (EOT) will be documented. The reported medications will be reviewed and evaluated by the Principal Investigator or designee to determine if they affect the participant's eligibility to participate in the study.

6.5.1 Rescue Medicine

If adequate pain relief was not achieved, then participants are permitted to take rescue medication, although they will be encouraged to wait 2 hours to allow the investigational product time to take effect. The study site will supply the rescue medication that will be obtained locally. Rescue medication will be dispensed in a hierarchical method starting with ibuprofen 400 mg. Should the participant not experience adequate pain relief, Hydrocodone 5 mg/Acetaminophen 325 mg tablets or other appropriate analgesics (such as an additional ibuprofen dose) may be used at the discretion of the Investigator. Rescue medication is also available on return of pain and the time of rescue medication will be recorded in the source documents. Pain assessments will be performed immediately before the first dose of rescue medication.

- Rating of Pain Intensity (NRS);
- Rating of Pain Relief (Categorical);
- Global Assessment of investigational product as a pain reliever.

All active stopwatch elapsed time(s) will be stopped at the time of rescue administration and recorded on the case report form.

Participants will be queried in a nonspecific fashion for any adverse events. All observed and reported AEs will be collected and recorded on the case report form. The information recorded will be based on signs and symptoms reported by the participant or observed by the research coordinator during clinical evaluation.

6.6 Dose Modification

The dosing schedule cannot be modified.

6.7 Intervention after the End of the Study

This study is a single dose administration after surgery and there is no additional treatment allocated. Participants who randomize into the study will be discharged from the study center after the final (24 hour post dosing) assessments, regardless of whether rescue medication had been taken or not.

7. Discontinuation of Study Intervention and Participant

7.1 Discontinuation of Study Intervention

See the SoA for data to be collected at the time of intervention discontinuation and follow-up and for any further evaluations that need to be completed.

7.2 Participant Discontinuation/Withdrawal from the Study

Withdrawal criteria

Participants *must* be withdrawn from the study if any of the following occurs:

- A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons. This is expected to be uncommon.
- At the time of discontinuing from the study, if possible, an early discontinuation visit should be conducted, as shown in the SoA. See SoA for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.
- The participant will be permanently discontinued both from the study intervention and from the study at that time.
- If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.
- Participant's pain intensity post-surgery at pre-dose does not exceed 'mild' and the NRS is <5 (see Section 10.5);
- If, in the Investigator's opinion, continuation of the study would be harmful to the participant's well-being;

Participants *may* be withdrawn from the study if any of the following occurs:

- Participant experiences one or more serious adverse events;
- At the specific request of the Sponsor and in consultation with the Investigator (e.g., obvious non-compliance, safety concerns);
- Protocol violation: if the participant develops conditions, which would have prevented his/her entry into the study according to the inclusion/exclusion criteria, he/she must be withdrawn immediately if safety is concerned; in other cases, the investigator will decide whether there is a conflict with the study objectives.

7.3 Lost to Follow Up

A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

The following actions must be taken if a participant fails to return to the clinic for a required study visit:

- The site must attempt to contact the participant and reschedule the missed visit as soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study.
- Before a participant is deemed lost to follow up, the investigator or designee must make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant's last known mailing address

or local equivalent methods). These contact attempts should be documented in the participant's medical record.

- Should the participant continue to be unreachable, he/she will be considered lost to follow up.

8. Study Assessments and Procedures

Study procedures and their timing are summarized in the SoA. Protocol waivers or exemptions are not allowed. Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine if the participant should continue or discontinue study intervention. Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the participant's routine clinical management (e.g., blood count) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA.

8.1 Efficacy Assessments

If not stated otherwise, the measures / actions listed in the following Sections [8.1.1](#) to [8.1.6](#) will be performed by a designated study team member as designated by the Principal Investigator.

8.1.1 Screening Period

Note: No screening procedures may be performed unless participants have been provided an IRB-approved written informed consent which participants have read, understood, and signed.

The Screening Period will be up to 28 days long. The following will be determined during the Screening Visit:

- Signed Informed Consent Form (ICF);
- Review inclusion and exclusion criteria;
- Participant demographics;
- Medical/surgical history including history of drug, alcohol, tobacco and caffeine use;
- Medication history of all prescription, OTC products including vitamins or dietary/herbal supplements, taken during the past 30 days;
- Vital signs consisting of sitting blood pressure (in triplicate with one min in between), respiratory rate and pulse after sitting for at least 5 minutes;

- Physical and oral examination;
- Dental x-ray examination and interpretation including impaction score;
Note: The medical interpretation may occur after the screening visit provided a diagnosis of impaction is determined prior to surgery.
- Urine tests for illicit drugs;
- Breath or saliva alcohol test;
- Urine pregnancy test (if applicable).

Upon satisfying the inclusion/exclusion criteria, eligible participants will be instructed to return to the trial site within 28 days for oral surgery. Participants will be instructed to refrain from the use of all medications (prescription, nonprescription, herbal supplements) unless in the opinion of the Investigator or Sponsor, the medication will not interfere with study procedures, data integrity, or compromise the safety of the participants.

Participants will be instructed not to consume alcohol or use any nicotine containing products 24 hours prior to surgery. Surgery will be scheduled between 0530 h and 1030 h.

The Principal Investigator or his/her designee must review participant's study records before qualifying the participant for the trial.

8.1.2 Pre-surgery

Participants are instructed to be nil per os (NPO) from midnight prior to surgery. If a participant had something to eat or drink after midnight, the surgeon must determine if surgery may proceed. Participants will arrive at the unit at their assigned time and will have the following activities completed prior to dental surgery:

- Review changes in the participant's medical/medication history and inclusion/exclusion criteria since previous visit;
- Urine tests for illicit drugs;
- Breath or saliva alcohol test;
- Vital signs consisting of sitting blood pressure (in triplicate with one min in between), respiratory rate and pulse after sitting for at least 5 minutes (-30 minutes);
- Urine pregnancy test (if applicable);
- Review pain assessment process and procedures.

8.1.3 Impaction Score

An Impaction Score will be used to assess each tooth based on the radiographic appearance and the intraoral examination. Each tooth will be rated from 1 to 4 using the following criteria: (1) erupted in tissue (2) soft tissue impaction (3) partial bony impaction, and (4) full bony impaction. Only participants whose mandibular impactions are scored (3) or (4) will be eligible to participate in the study.

8.1.4 During Surgery

During surgery, participants will be administered a short acting local anesthetic (lidocaine or mepivacaine with or without vasoconstrictor) and nitrous oxide; at the discretion of the oral surgeon. Topical anesthetics may also be used prior to the administration of the short acting local anesthetic. Long duration local anesthetics like bupivacaine are not permitted. No other perioperative analgesic or anesthetic agents are permitted. Perioperative corticosteroids are not permitted.

8.1.5 Surgical Trauma Score

At the completion of the procedure, the surgeon will rate the degree of surgical trauma on a of (1) mild, (2) moderate or (3) severe. Only individuals with a surgical trauma rating of mild (1) or moderate (2) will be eligible to participate in the study.

8.1.6 Postsurgery

During the post-surgery recovery period, participants will rest quietly, but will be encouraged not to fall asleep. Participants will be permitted to drink clear liquids following surgery. Participant may incorporate foods according to a soft diet following dosing beginning 60 minutes after dosing. Participants will not be allowed to eat 30 minutes prior to any planned assessments.

In order to qualify for randomization and continue in the trial, participants must have 'moderate' or 'severe' postoperative pain intensity on the Categorical Pain Rating Scale **and** a score of ≥ 5 on the NRS within 4.5 hours of the last suture.

Eligible participants will be assigned a participant randomization number and investigational products will be administered according to a generated randomization schedule (see Section 6.1.1).

Participants who have not met the randomization criteria within 4.5 hours from last suture or 14:30 h (+/- 15 minutes) will not be randomized and may be discharged from the clinic, once deemed eligible by an Investigator. Prior to being released from the clinic, discharge procedures will be reviewed with the participant. When discharged, all participants will need to make prior arrangements for travel and should not drive themselves home.

After the baseline (pre-dose) pain intensity is determined, pain intensity and pain relief will be rated by participants at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours (+/-5 minutes over the first 8 hours; +/-8 minutes from hours 9 through 24) post-dose, and immediately prior to the use of the first dose rescue medication.

Instructions will be provided for use of the two stopwatches. A double-stopwatch method will be used to record time up to 24 hours after dosing for time to "first perceptible pain relief" (stopwatch A) and time to "meaningful pain relief *determined*" (stopwatch B). When the participant is administered study medication (following mouth inspection), the Study Coordinator or designee will start two stopwatches (one designated A and one designated B). The faces of the stopwatches will be covered so that the participant remains blinded to the exact time. To determine the time when the participant begins to perceive pain relief, the participant will be given stopwatch A after dosing and will be instructed to:

"Stop the stopwatch when you first begin to feel any pain-relieving effect whatsoever of the drug. That is, when you first feel a little relief. This does not necessarily mean that you feel completely better, although you might, but when you first feel any difference in the pain that you have now."

The participant will notify the Study Coordinator as soon as this stopwatch is stopped. The elapsed time on stopwatch A will be recorded in the case report form as the time to **first perceptible pain relief**. The participant will then be asked:

"Do you consider the relief you experienced meaningful?"

This answer will be recorded by the study coordinator in the case report form. If the participant answers "Yes" to this question, then meaningful pain relief is confirmed. The time recorded in the case report form for time to **meaningful pain relief confirmed will be the same time recorded as first perceptible pain relief**. The participant will not be given the second stopwatch. If the participant does not consider the relief to be meaningful, (by stating No), the participant will be given a second, covered stopwatch with instructions to:

"Stop this stopwatch when you have meaningful relief, that is, when the relief from the pain is meaningful to you."

The elapsed time on stopwatch B will be recorded in the case report form as time to **meaningful pain relief determined**. Unless meaningful pain relief is achieved, the participant will always have an active stopwatch in front of them.

If the participant never experiences first perceptible pain relief, they will retain stopwatch A for the entire 24-hour evaluation period. If the participant experiences first perceptible pain relief but not any meaningful pain relief (confirmed or determined), they will retain stopwatch B for the remainder of the 24-hour evaluation period.

Participants would be encouraged not to sleep before midnight and if needed, woken for assessments (up to hour 14). Participants will be allowed a 6 hour rest period during the overnight hours of the 24-hour evaluation period and woken for the 22 hour assessment. The order of the pain assessments is Pain Intensity, then Pain Relief, then query about any AEs. At hour 24 or immediately prior to the first dose of rescue medication (if prior to hour 24), study participants will be asked to provide a Global Assessment of investigational product after completion of the other assessments. Additionally, participants will have vital signs taken after surgery, then at 1, 12 and 24 hours (+30 minutes post-surgery; +/-30 minutes from hours 1 through 24) post-dose.

Throughout the treatment period, the participants will be monitored for the occurrence of adverse events. Symptoms will be assessed by spontaneous reporting of AEs and by asking the participants to respond to a non-leading question such as "How do you feel?" or "Are you experiencing any other effects?" All reported or observed AEs will be collected and recorded on the case report form. The information will be based on signs and symptoms reported by the participant or observed by the study personnel staff during clinical evaluation.

If a participant has any clinically significant, trial-related abnormalities at the conclusion of the treatment period, the clinical monitor (or designated representative) should be notified and the participant should be asked to remain at the trial site until such abnormalities are stabilized or resolve. If the participant is unable or unwilling to remain at the trial site, the clinical monitor (or designated representative) should be notified, and the Investigator should make every effort to arrange follow-up evaluations at appropriate intervals to document the course of the abnormalities.

Participants will be allowed the use of ice following the use of rescue medication. Ice will not be permitted for participants prior to randomization until after they have been administered rescue medication (if applicable). If participant has been administered rescue, ice will be given as requested by the participant for 20 minute increments. Upon completion of all trial procedures, participants will be discharged from the trial site. Participants will need to make prior arrangements for travel and should not drive themselves home.

8.2 Safety Assessments

Safety measures will be analyzed for all participants in the safety population.

Adverse events will be collected throughout the treatment and safety follow-up periods and will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary. Only treatment-emergent AEs will be included, i.e., AEs that begin or worsen after the first dose of the investigational products in the treatment period. The number and percent of participants who experience any event, by System Organ Class (SOC), and by Preferred Term will be displayed by treatment group. Tables will also be produced by severity and relationship to investigational product. Seriousness, severity, relationship to investigational product, duration, and outcome will also be listed.

Planned time points for all safety assessments are provided in the SoA.

8.2.1 Physical Examinations

The physical examination (by means of inspection, palpation, auscultation) will be performed by qualified medical staff (e.g., a physician, oral surgeon, nurse practitioner or physician assistant) at the study site covering at least the organs of the head/neck, cardiovascular, and respiratory systems.

Abnormal physical examination findings are recorded either as medical history or as adverse events (see Section [10.3.1](#)).

8.2.2 Vital Signs

Systolic and diastolic blood pressure and heart rate will be measured (in triplicates allowing one minute in between measurements) by a member of the investigator's team under the following conditions:

- Systolic blood pressure (after resting for at least 5 min in sitting position);
- Diastolic blood pressure (after resting for at least 5 min in sitting position);
- Heart rate (after resting for at least 5 min in sitting position);

- Measuring site: cuff to be placed on the right / left upper arm (if possible, the same arm will be used for all measurements in one participant); cuff location will be documented;
- Method: oscillometric by automatic measurement device.

Blood pressure is to be taken in triplicates, one minute apart to enhance accuracy as suggested in the FDA guidance (Assessment of Pressor Effect of Drugs, May, 2018). Pre-surgery vitals may be collected up to 30 minutes prior to time of surgery.

8.2.3 Clinical Safety Laboratory Assessments

Urine samples will be collected by a member of the investigator's team, for time points and parameters see Section 1.3.

8.2.4 Other Procedures and Variables

Eligible participants will undergo an oral examination and a dental x-ray (radiograph) exam to confirm that impacted third molar teeth are present.

8.3 Adverse Events and Serious Adverse Events

The definitions of an AE or SAE can be found in Section 10.3.

AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative or health care professional not involved in the study).

The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE. They remain responsible for following up SAEs, or AEs considered related to the study intervention or study procedures, or those that caused the participant to discontinue the study.

8.3.1 Time Period and Frequency for Collecting AE and SAE Information

All AEs and SAEs will be collected from the signing of the ICF until the follow up visit at the time points specified in the SoA (Section 1.3).

Medical occurrences that begin before the start of study intervention but after obtaining informed consent will be recorded on the Medical History/Current Medical Conditions section of the case report form (CRF) not the AE section.

All SAEs will be recorded and reported to the sponsor or designee immediately and under no circumstances should this exceed 24 hours, as indicated in Section 10.3.2. The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.

Investigators are not obligated to actively seek AE or SAE after conclusion of the study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the sponsor.

8.3.2 Expected Adverse Events

For this study, the applicable reference document is the most current version of the DFL and IB for naproxen and caffeine. If relevant new safety information is identified, the information will be integrated into an update of the safety information and distributed to all participating sites.

The expectedness of AEs will be determined by the sponsor according to the applicable reference document and according to all local regulations.

8.3.3 Method of Detecting AEs and SAEs

The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Section 10.3.

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrences.

8.3.4 Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is given in Section 10.3.

8.3.5 Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of an SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.

Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the sponsor will review and then file it along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to local requirements. Send the SAE CRF pages and complementary forms to:

cc-consreldept@bayer.com (in the USA)

8.3.6 Pregnancy

A participant's participation is to be terminated immediately if a pregnancy is supposed (i.e. in case her pregnancy test becomes positive).

The investigator must report to the sponsor any pregnancy occurring in a female study participant during her participation in this study. The outcome of the pregnancy should be followed up carefully, and any outcome of the mother and the child at delivery should be reported. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

For a pregnancy in the partner of a male study participant, all efforts will be made to obtain similar information on course and outcome, participant to the partner's consent.

For all reports, the forms provided are to be used. The investigator should submit them within the same timelines as a SAE (see Section 8.3.5). Send the completed pregnancy forms to:

cc-consreldept@bayer.com (in the USA)

8.4 Treatment of Overdose

For this study, any dose of study intervention greater than single dose study intervention within a 12-hour time period will be considered an overdose.

The sponsor does not recommend specific treatment for an overdose.

In the event of an overdose, the investigator/treating physician should:

- Contact the Medical Monitor immediately;
- Closely monitor the participant for any AE/SAE;
- Document the quantity of the excess dose as well as the duration of the overdose in the CRF.

8.5 Pharmacokinetics

Pharmacokinetic parameters are not evaluated in this study.

8.6 Pharmacodynamics

Pharmacodynamic biomarker parameters are not evaluated in this study.

8.7 Genetics

Genetic testing is not performed in this study.

8.8 Biomarkers

Biomarkers are not evaluated in this study.

8.9 Health Economics

Health Economics/Medical Resource Utilization and Health Economics parameters are not evaluated in this study.

9. Statistical Considerations

Statistical analysis will be performed using statistical analysis software (SAS) and the version used will be specified in the Statistical Analysis Plan (SAP) and placed on file. The SAP will contain a more comprehensive explanation than described below of the methodology used in the statistical analyses. The SAP will also contain the rules and data handling conventions used to perform the analyses, and the procedure used for accounting for missing data.

9.1 Statistical Hypotheses

The primary efficacy endpoint is the sum of change in pain intensity from 0 to 8 hours (SPID₀₋₈). The treatment comparisons will be made in the following sequential order for SPID₀₋₈ (each at 0.05 level of significance) in order to protect overall type 1 error at 0.05:

- Naproxen sodium/caffeine 220/65 mg versus Naproxen sodium 220 mg
- Naproxen sodium/caffeine 440/130 mg versus Naproxen sodium 220 mg
- Naproxen sodium/caffeine 220/65 mg versus Naproxen sodium/caffeine 440/130 mg

Once a comparison is statistically non-significant, the subsequent comparisons will be technically ineligible to be declared significant. However, all pairwise comparisons will be presented to provide a complete picture.

9.2 Sample Size Determination

Assuming that the treatment difference between the combo and naproxen alone of 6.5 and common standard deviation of 16.9 with respect to SPID₀₋₈, a total of approximately 528 subjects (144 subjects per active treatment arm and 48 in the caffeine and placebo using a 3:3:3:1:1 ratio) are required to achieve 90% of power with the type I error of 0.05, a total of approximately 556 subjects will be randomized into the study if a drop-out rate of 5% is assumed.

9.3 Populations for Analyses

For purposes of analysis, the following populations are defined:

Population	Description
Safety	All participants who are randomized and take at least one dose of investigational product. Safety measures will be analyzed for all participants in the safety population.
Intent-To-Treat (ITT)	All participants in the Safety Population. ITT population will be used as the primary analysis for the efficacy parameters.
Per Protocol (PP) Population	<p>PP population will include all participants in ITT who do not have any major protocol violations and complete the 24 hour assessments. PP population will be used as secondary to conduct the sensitivity analysis for the selected parameters.</p> <p>Major protocol deviations will be identified prior to database lock and may include but are not limited to significant violations of inclusion/exclusion criteria, noncompliance of the trial treatment taken, conditions such as vomiting and diarrhea or use of prohibited medications, and not following clinical trial protocol procedures. Any participant who rescues or vomits at or prior to 60 minutes after ingesting study medication will be excluded from the PP population.</p>

9.4 Statistical Analyses

The statistical analysis plan (SAP) will be developed and finalized before database lock and will describe the participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.

9.4.1 Efficacy Analyses

For each post-dose time point, Pain Intensity Differences (PID) will be derived by subtracting the pain intensity at the post-dose time point from the baseline intensity score (baseline score – post-baseline score). A positive difference is indicative of improvement. Time-weighted Sum of Pain Intensity Differences (SPIDs) will be calculated for 2, 4, 6, 8, 12, 16, 20 and 24 hours by multiplying the PID score at each post-dose time point by the duration (in hours)

since the preceding time point and then summing these values over 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours, respectively.

Similarly, Total Pain Relief Scores (TOTPARs), will be calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values.

In all analyses for participants who take rescue medication, all pain intensity scores after intake of rescue medication will be imputed by the worse of the baseline or the score assessed immediately before taking rescue medication. All pain relief after intake of rescue medication will be imputed by “no relief” (0).

Endpoint	Statistical Analysis Methods
Primary	<p>The primary efficacy analyses population will be based on the ITT population.</p> <p>Sum of Pain Intensity Difference over 8 hours: SPID₀₋₈ be analyzed using an analysis of covariance model (ANCOVA) with treatment as fixed effect and baseline pain intensity score as the covariate. A 95% of confidence interval (CI) for the treatment differences and pairwise p-values will be calculated based on the above mentioned model.</p>
Secondary	<p>Total Pain Relief over 8 hours: TOTPAR₀₋₈ will be analyzed similarly as for the primary endpoint.</p> <p>Time to first use of rescue medication. If a participant did not take the rescue medication during the treatment period, (s)he will be censored at the time of last assessment. Time to first use of rescue medication will be estimated and plotted using Kaplan-Meier method and analyzed using log-rank test.</p>

Secondary	<p>The SPID₀₋₂, 0-4, 0-6, 6-12, 0-12, 12-16, 16-20, 12-24, 16-24 and 0-24 will be analyzed using the same methodology as for SPID₀₋₈.</p> <p>TOTPAR₀₋₂, 0-4, 0-6, 6-12, 0-8, 0-12, 12-16, 16-20, 12-24, 16-24 and 0-24 will be analyzed using the same methodology as for SPID₀₋₈.</p> <p>Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, (16, 18, 20 if awake), 22 and 24 hours post-dose. Descriptive statistics for each time point and graphical illustrations of the time effect curves will be presented.</p> <p>Time to first perceptible relief measured by a stopwatch, time to meaningful relief measured by a stopwatch, and time to first perceptible relief confirmed by meaningful relief defined as the time to perceptible pain relief (the first stopwatch time) for those participants who had meaningful pain relief (the second stopwatch time) will be analyzed similarly as for the time to first use of rescue medication.</p> <p>Time to achieve complete pain relief will be analyzed similarly as for the time to first use of rescue medication.</p> <p>The cumulative proportion of participants taking rescue medication over time will be analyzed using Chi-square tests and curves over time will be plotted. Frequency tables will be tabulated for the number of times that the participant took rescue medication over the 24 hour period.</p> <p>Peak PID and peak pain relief will be analyzed descriptively.</p> <p>Cumulative percent of participants with 'at least a 2-point PID' and cumulative percent of participants achieving complete pain relief will be plotted over time and will be analyzed using Chi-square tests.</p> <p>Global Assessment of the investigational product will be analyzed using CMH method with modified ridit score.</p>
-----------	---

9.4.2 Safety Analyses

All safety analyses will be performed on the Safety Population.

Endpoint	Statistical Analysis Methods
Secondary	<p>AEs produced by severity and relationship to study intervention. Seriousness, severity, relationship to each study intervention duration, and outcome will also be listed.</p> <p>Quantitative data for blood pressure, heart rate, body weight, body temperature will be described by summary statistics for the original data as well as for the change from baseline. Frequency tables will be provided for qualitative data. Laboratory data outside the reference range will be listed and highlighted with 'L' for low and 'H' for high. An additional table with all abnormal values will be presented.</p>

9.5 Interim Analyses

No interim analysis will be performed.

10. Supporting Documentation and Operational Considerations

10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1 Regulatory and Ethical Considerations

- This study will be conducted in accordance with the protocol and with the following:
 - Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
 - Applicable ICH Good Clinical Practice (GCP) Guidelines
 - Applicable laws and regulations

The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated. Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.

The investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures

- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

10.1.2 Financial Disclosure

Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

10.1.3 Funding

This study will be funded by its sponsor.

10.1.4 Informed Consent Process

All relevant information on the study will be summarized in an integrated participant information sheet and informed consent form provided by the sponsor or the study center. Sample participant information and informed consent/assent forms are provided as a document separate to this protocol. Participants 16 to 17 years old who cannot legally give informed consent for research participation must use an IRB-approved assent form and a Parental/Guardian informed consent form. Informed consent must first be obtained from the child's parent or legal guardian before assent may be obtained from the child.

Based on this participant information sheet, the investigator or his/her representative will explain the nature of the study to the participant or his/her legally authorized representative and answer all questions regarding the study. Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.

The investigator will also mention that written approval of the IRB has been obtained.

Each participant will be informed about the following aspects of premature withdrawal:

- Each participant has the right to withdraw from the study at any time without any disadvantage and without having to provide reasons for this decision;
- The participant's consent covers EOT examinations as specified in the visit description described in Section 7.2 to be conducted after withdrawal of consent;
- The participant's data that have been collected until the time of withdrawal will be retained and statistically analyzed in accordance with the statistical analysis plan;
- Participant-specific data on the basis of material obtained before withdrawal may be generated after withdrawal (e.g., image reading, analysis of biological specimen such as blood, urine or tissues); these data would also be retained and statistically analyzed

in accordance with the statistical analysis plan. The participant has the right to object to the generation and processing of this post-withdrawal data. For this, he/she needs to sign a corresponding declaration of objection; alternatively, the participant's oral objection may be documented in the participant's source data.

Each participant will have ample time and opportunity to ask questions.

Only if the participant agrees to sign the informed consent form and has done so, may he/she enter the study. Additionally, the investigator will personally sign and date the form. The participant will receive a copy of the signed and dated form.

The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. In the event that informed consent is obtained on the date that baseline study procedures are performed, the study record or participant's clinical record must clearly show that informed consent was obtained prior to these procedures.

For minors or adults under legal protection, consent shall be given by the legal guardian(s). The consent of a minor or adult under legal protection shall also be requested where such a person is able to express his/her own will. His/her refusal or the withdrawal of his/her consent may not be disregarded.

The informed consent form and any other written information provided to participants will be revised whenever important new information becomes available that may be relevant to the participant's consent, or there is an amendment to the protocol that necessitates a change to the content of the participant information and / or the written informed consent form. The investigator will inform the participant of changes in a timely manner and will ask the participant to confirm his/her participation in the study by signing the revised informed consent form. Any revised written informed consent form and written information must receive the IRB's approval / favorable opinion in advance of use.

Participants who are rescreened are required to sign a new ICF.

10.1.5 Data Protection and Confidentiality

Any participant records or datasets that are transferred to the sponsor will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred. The participant must be informed that his/her personal study-related data will be used by the sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant. The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/IEC members, and by inspectors from national or international regulatory authorities.

All records identifying the participant will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available.

Participant names will not be supplied to the sponsor. Only the participant numbers (SNR and RNR) will be recorded in the CRF/eCRF data collection system, and if the participant name appears on any other document (e.g., pathologist report), it must be obliterated before a copy of the document is supplied to the sponsor. Study findings stored on a computer will be

stored in accordance with local data protection laws. As part of the informed consent process, the participants will be informed in writing that representatives of the sponsor, IRB, or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data protection laws.

If the results of the study are published, the participant's identity will remain confidential.

The investigator will maintain a list to enable participants to be identified.

10.1.6 Compensation for Health Damage of Participants / Insurance

The sponsor maintains clinical trial insurance coverage for this study in accordance with the laws and regulations of the country in which the study is performed.

10.1.7 Committees Structure

Not applicable

10.1.8 Dissemination of Clinical Study Data

The sponsor will make the information regarding the study publicly available on the internet at www.clinicaltrials.gov as applicable to local regulations.

All data and results and all intellectual property rights in the data and results derived from the study will be the property of the sponsor who may utilize them in various ways, such as for submission to government regulatory authorities or disclosure to other investigators.

Regarding public disclosure of study results, the sponsor will fulfill its obligations according to all applicable laws and regulations. The sponsor is interested in the publication of the results of every study it performs.

10.1.9 Data Handling and Quality Assurance

The data collection tool for this study will be a validated electronic data capture system to be used at the study site. Participant data necessary for analysis and reporting will be provided to the Sponsor in CDISC (Clinical Data Interchange Standards Consortium) standards.

Clinical data management will be performed in accordance with applicable sponsor's/CRO's standards and data cleaning procedures. This is applicable for data recorded on the CRF/eCRF data collection system as well as for data from other sources (e.g., laboratory).

For data coding (e.g., AEs, medication), internationally recognized and accepted dictionaries will be used.

Reasons for missing data, especially inability to perform a test, must be documented.

All participant data relating to the study, except operative medications will be recorded on a CRF/eCRF data collection system unless transmitted to the sponsor or designee electronically (e.g., laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents. Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques are provided in the monitoring plan or applicable monitoring SOP.

The sponsor or designee is responsible for the data management of this study including quality checking of the data. The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract Research Organizations).

Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for 10 years (US), 25 years (Canada) after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor.

10.1.10 Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator's site.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

10.1.11 Missing Data

Reasons for missing data, especially inability to perform a test, must be documented.

10.1.12 Audit and Inspection

To ensure compliance with GCP and regulatory requirements, a member of the sponsor's (or a designated CRO's) quality assurance unit may arrange to conduct an audit to assess the performance of the study at the study site and of the study documents originating there. The investigator/institution will be informed of the audit outcome.

In addition, inspections by regulatory health authority representatives and IEC(s)/IRB(s) are possible. The investigator should notify the sponsor immediately of any such inspection.

The investigator/institution agrees to allow the auditor or inspector direct access to all relevant documents and allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any issues. Audits and inspections may occur at any time during or after completion of the study.

10.1.13 Archiving

Essential documents shall be archived safely and securely in such a way that ensures that they are readily available upon authorities' request.

Participant files will be archived according to local regulations and in accordance with the maximum period of time permitted by the hospital, institution or private practice. Where the archiving procedures do not meet the minimum timelines required by the sponsor, alternative arrangements must be made to ensure the availability of the source documents for the required period.

The investigator / institution notifies the sponsor if the archival arrangements change (eg relocation or transfer of ownership). The investigator site file is not to be destroyed without the sponsor's approval. The contract with the investigator/institution will contain all regulations relevant for the study center.

10.1.14 Study and Site Closure

The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.

Reasons for the early closure of a study site by the sponsor or investigator may include but are not limited to:

- Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
- Inadequate recruitment of participants by the investigator
- Discontinuation of further study intervention development

10.1.15 Publication Policy

The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.

The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

10.2 Appendix 2: Clinical Laboratory Tests

Urine samples will be collected by a member of the investigator's team, for time points and parameters see Section 1.3. Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1 Definition of AE

AE Definition

- An AE is any untoward medical occurrence in a patient or clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.
- NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) associated with the use of study intervention.

Events Meeting the AE Definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator.
- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.
- "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE.

Events NOT Meeting the AE Definition

- Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant's condition.
- Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.

10.3.2 Definition of SAE

An SAE is defined as any untoward medical occurrence that, at any dose:

a. Results in death**b. Is life-threatening**

- The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. Requires inpatient hospitalization or prolongation of existing hospitalization

- In general, hospitalization signifies that the participant has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred or was necessary, the AE should be considered serious.
- Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.

d. Results in persistent disability/incapacity

- The term disability means a substantial disruption of a person's ability to conduct normal life functions.
- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect

f. Other situations:

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
 - Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.
-

10.3.3 Recording and Follow-Up of AE and/or SAE

AE and SAE Recording

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event.
- The investigator will then record all relevant AE/SAE information in the CRF.
- It is not acceptable for the investigator to send photocopies of the participant's medical records in lieu of completion of the AE/SAE CRF page.
- There may be instances when copies of medical records for certain cases are requested by the sponsor. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before submission.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of Intensity

The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to one of the following categories:

- Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities.
- Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.
- Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.
- An event is defined as 'serious' when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.

Assessment of Causality

- The investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE.
- A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
- Possible answers are "yes" or "no"
- An assessment of "no" would include:
 - The existence of a highly likely alternative explanation, e.g., mechanical bleeding at surgical site.

or

-
- Non-plausibility, e.g., the participant is struck by an automobile when there is no indication that the drug caused disorientation that may have caused the event; cancer developing a few days after the first drug administration.

An assessment of “yes” indicates that the AE is reasonably associated with the use of the study treatment.

- The investigator will use clinical judgment to determine the relationship.
- Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.
- The investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for marketed products, in his/her assessment.
- For each AE/SAE, the investigator **must** document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report. However, **it is very important that the investigator always make an assessment of causality for every event before the initial transmission** of the SAE data.
- The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is one of the criteria used when determining regulatory reporting requirements.

Causal relationship to protocol-required procedure(s)

The assessment of a possible causal relationship between the AE and protocol-required procedure(s) is based on the question whether there was a “reasonable causal relationship” to protocol-required procedure(s).

Possible answers are “yes” or “no”

Action taken with study intervention

Any action on study treatment to resolve the AE is to be documented using the categories listed below.

The study treatment action should be recorded separately for each study treatment as detailed in the CRF/eCRF data collection system.

- Drug withdrawn
 - Drug interrupted
 - Not applicable
 - Unknown
-

Other specific treatment(s) of adverse event

- None
- Remedial drug therapy
- Other

Outcome of adverse event

The outcome of the AE is to be documented as follows:

- Recovered/resolved
- Recovering/resolving
- Recovered/resolved with sequelae
- Not recovered/not resolved
- Fatal
- Unknown

Follow-up of AEs and SAEs

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- New or updated information will be recorded in the originally completed CRF.
- The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of the information.

10.3.4 Reporting of SAEs

SAE Reporting to the Sponsor via Paper CRF/Complementary pages

- Email or facsimile transmission of the SAE paper CRF as well as the complementary pages provided is the preferred method to transmit this information to Bayer's Pharmacovigilance department (see Section [8.3.5](#)).
 - In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
 - Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF and complementary pages within the designated reporting time frames.
-

10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information

Definitions:

Woman of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP

1. Premenarchal
2. Premenopausal female with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's: review of the participant's medical records, medical examination, or medical history interview.

1. Postmenopausal female
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement [insert threshold if required (>40 IU/L or mIU/mL) or remove to allow for flexibility with different local thresholds for defining postmenopausal state] is required.
 - Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
 - The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the sponsor within 24 hours of learning of a participant's pregnancy.

- The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow-up information on the participant and the neonate, after obtaining the signed informed consent from both parents, unless local law or specific circumstances of the respective case allow otherwise, and the information will be forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study intervention by the investigator will be reported to the sponsor as described in Section 8.3.5. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting.
- Any female participant who becomes pregnant while participating in the study will discontinue study intervention or be withdrawn from the study.

Collection of Pregnancy Information:**Male participants with partners who become pregnant**

- The investigator will attempt to collect pregnancy information on any male participant's female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive study intervention.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the appropriate form and submit it to the sponsor within 24 hours of learning of the partner's pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.

Female Participants who become pregnant

- The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the sponsor within 24 hours of learning of a participant's pregnancy.

- The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow-up information on the participant and the neonate, after obtaining the signed informed consent from both parents, unless local law or specific circumstances of the respective case allow otherwise, and the information will be forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study intervention by the investigator will be reported to the sponsor as described in Section 8.3.6. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting.
- Any female participant who becomes pregnant while participating in the study will be withdrawn from the study.

10.5 Appendix 5: Participant Assessments**Categorical Pain Intensity Scale (predose)**

Finish the statement: “**My pain at this time is**” by checking the appropriate box.

- ☐ No Pain (0)
- ☐ Mild Pain (1)
- ☐ Moderate Pain (2)
- ☐ Severe Pain (3)

Numerical Rating Scale (pre-dose and post-dose)

Circle a number to indicate level of pain (from 0 to 10) below to indicate the severity of the pain you are experiencing at this time.

No pain	0	1	2	3	4	5	6	7	8	9	10	Worst possible pain
------------	---	---	---	---	---	---	---	---	---	---	----	---------------------------

Categorical Pain Relief Rating Scale (post-dose)

Finish the statement: “ **My relief from my starting pain is**” by checking the appropriate box.

- ☐ No Relief (0)
- ☐ A Little Relief (1)
- ☐ Some Relief (2)
- ☐ A Lot of Relief (3)
- ☐ Complete Relief (4)

Global Assessment of Pain (post-dose)

Finish the statement: “ *What is your overall rating of the study medication you received?*”
by checking the appropriate box.

- ☐ Poor (0)
- ☐ Fair (1)
- ☐ Good (2)
- ☐ Very Good (3)
- ☐ Excellent (4)

10.6 Appendix 6: Abbreviations

AE	Adverse Event
ANCOVA	Analysis of Covariance
CDER	Center for Drug Evaluation and Research
CDISC	Clinical Data Interchange Standards Consortium
CI	Confidence Interval
COX	Cyclooxygenase
CRO	Clinical Research Organization
CSR	Clinical Study Report
(e)CRF	(electronic) Case Report Form
EOT	End of Trial
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GMP	Good Manufacturing Practice
IB	Investigator Brochure
ICF	Informed Consent Form
ICH	International Conference on Harmonization
IRB/IEC	Institutional Review Board/Independent Ethics Committee
ITT	Intent-to-Treat
MedDRA	Medical Dictionary for Regulatory Activities
NPO	nil per os
NRS	Numerical Rating Scale
NSAID	Nonsteroidal Anti-inflammatory Drug
OTC	Over-the-Counter
PID	Pain Intensity Differences
PP	Per Protocol
QA	Quality Assurance
RNR	Randomization Number
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SAS	Statistical Analysis Software
SNR	Screening Number
SSRI	Selective Serotonin Uptake Inhibitors
SoA	Schedule of Activities
SOC	System Organ Class
SPID	Summed Pain Intensity Difference
SUSAR	Serious Unexpected Adverse Reaction
TEAE	Treatment-Emergent Adverse Event
TOTPAR	Total Pain Relief
UI	Unique Identification (formulation)

11. References

Moderate caffeine consumption during pregnancy. Committee Opinion No. 462. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2010;**116**: 467–8.

Capone, M. L., S. Tacconelli, M. G. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P. Di Gregorio, G. Merciaro, C. Patrono and P. Patrignani (2004). "Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects." *Circulation* **109**(12): 1468-1471.

Cooper, S. A. and W. T. Beaver (1976). "A model to evaluate mild analgesics in oral surgery outpatients." *Clin Pharmacol Ther* **20**(2): 241-250.

Cooper, S. A., P. J. Desjardins, D. C. Turk, R. H. Dworkin, N. P. Katz, H. Kehlet, J. C. Ballantyne, L. B. Burke, E. Carragee, P. Cowan, S. Croll, R. A. Dionne, J. T. Farrar, I. Gilron, D. B. Gordon, S. Iyengar, G. W. Jay, E. A. Kalso, R. D. Kerns, M. P. McDermott, S. N. Raja, B. A. Rappaport, C. Rauschkolb, M. A. Royal, M. Segerdahl, J. W. Stauffer, K. H. Todd, G. F. Vanhove, M. S. Wallace, C. West, R. E. White and C. Wu (2016). "Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations." *Pain* **157**(2): 288-301.

Derry, C. J., S. Derry and R. A. Moore (2014). "Caffeine as an analgesic adjuvant for acute pain in adults." *Cochrane Database Syst Rev*(12): CD009281.

Derry, S., P. J. Wiffen and R. A. Moore (2015). "Single dose oral ibuprofen plus caffeine for acute postoperative pain in adults." *Cochrane Database Syst Rev*(7): CD011509.

Diener, H. C., V. Pfaffenrath, L. Pageler, H. Peil and B. Aicher (2005). "The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study." *Cephalalgia* **25**(10): 776-787.

Fricke, J. R. (1994). A Single-Dose Efficacy and Safety Comparison of Naproxen Sodium Plus Caffeine to Naproxen Sodium, Caffeine, and Placebo in Dental Pain, Syntex Laboratory.

Grosser, T., K. N. Theken and G. A. FitzGerald (2017). "Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System." *Clin Pharmacol Ther* **102**(4): 611-622.

Laska, E. M., A. Sunshine and F. Mueller (1984). "Caffeine as an analgesic adjuvant." *Journal of the American Medical Association* **251**(13): 1711-1718.

Laska, E. M., A. Sunshine, F. Mueller, W. B. Elvers, C. Siegel and A. Rubin (1984). "Caffeine as an analgesic adjuvant." *JAMA* **251**(13): 1711-1718.

Lipton, R. B., H. C. Diener, M. S. Robbins, S. Y. Garas and K. Patel (2017). "Caffeine in the management of patients with headache." *J Headache Pain* **18**(1): 107.

McGuire, S. (2014). "Institute of Medicine. 2014. Caffeine in Food and Dietary Supplements: Examining Safety-Workshop Summary. Washington, DC: The National Academies Press, 2014." Adv Nutr **5**(5): 585-586.

Sawynok, J. (2011). "Caffeine and pain." Pain **152**(4): 726-729.

Sawynok, J. and T. L. Yaksh (1993). "Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action." Pharmacol Rev **45**(1): 43-85.

Weiser, T., E. Richter, A. Hegewisch, D. D. Muse and R. Lange (2018). "Efficacy and safety of a fixed-dose combination of ibuprofen and caffeine in the management of moderate to severe dental pain after third molar extraction." Eur J Pain **22**(1): 28-38.